Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

  • STATUS
    Recruiting
  • participants needed
    36
  • sponsor
    Innovent Biologics (Suzhou) Co. Ltd.
Send
Updated on 5 August 2020
See if I qualify

Summary

This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Male and Female Subjects being Overweight or with Obesity.

Details
Condition Overweight or Obesity
Age 18years - 75years
Treatment Placebo, IBI362
Clinical Study IdentifierNCT04440345
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Have stable body weight for the past 12 weeks prior to screening
Have a body mass index (BMI) 24 kilograms per meter squared (kg/m) with complication, or BMI28 kg/m,inclusive at screening
Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff

Exclusion Criteria

Have a diagnosis of type 2 diabetes
Have received prescription drugs or over the counter drugs that promote weight loss in the past 3 months prior to screening
Previous treatment with a GLP-1 (glucagon-like peptide 1) receptor agonists or GCG(glucagon)receptor agonists before
Surgical treatment for obesity
Past or current chronic or idiopathic pancreatitis, or any of the following: -amylase or lipase above 2 times UNR (upper normal range), triglycerides above 500 mg/dL
Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study
Unwilling to comply with smoking and alcohol restrictions during the study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.